Back to list

The race for an effective vaccine


  • The European Union has already started vaccinating its population after each EU member states received almost 10,000 doses of the Pfizer/BioNTech vaccine on December 26. Deliveries will continue in January and on a steady weekly basis during the following months. The distribution of the full 200 million doses is scheduled to be completed by September 2021


  • On December 31, the World Health Organization gave Pfizer & BioNTech vaccine an emergency use listing, which will speed up its authorization in many other countries. Pfizer & BioNTech vaccine had already been approved for full use in several countries including Canada and for emergency use in The US, Europe and across South America and Asia.


  • The United Nations put in place a global mechanism named COVAX facilities which aims to deliver two billion doses by the end of 2021, and to make sure that these doses are affordable and available to all.


Quick fact: A vaccine being approved means it has been through several phases of testing on tens thousands of people and showed satisfactory results approved by regulators. It is the last step before manufacturing and distribution.


Coping with the pandemic

  • British scientists are trialing a new drug that could prevent someone who has been exposed to coronavirus from going on to develop the disease Covid-19. It could be available as soon as March or April if it is approved by the medicines regulator and would protects against Covid-19 for between six to twelve months.


  • Taiwanese scientists have developed a decoy antibody that can prevent infection by the coronavirus by blocking it from entering human cells. In the abstract of their peer-reviewed article published on November 30, the scientists explain these promising characteristics potentiate the therapeutic prospects of ACE2‐Fc as an effective treatment for COVID‐19.

With 28 years of professional experience,
UKEAS provides whole range of counselling service for your dream blueprint.
By continuing to use this site, you agree to the use of cookies. Click here for our full privacy policy